# Safety and Tolerability Study With Single Ascending Doses of ODM-102

> **NCT01839019** · PHASE1 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 22 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** ODM-102
- **DRUG:** Placebo for ODM-102

## Key facts

- **NCT ID:** NCT01839019
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2013-06
- **Final completion:** 2013-08
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01839019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01839019, "Safety and Tolerability Study With Single Ascending Doses of ODM-102". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01839019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*